14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TRVI vs DMAC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Trevi Therapeutics, Inc. (TRVI) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). TRVI carries a Unified Composite Score of 42.9/100 (HOLD) at $13.34 (N/M Forward P/E, 0.0% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TRVI vs DMAC. Trailing 12-month operating profitability (TRVI 0.0% vs DMAC 0.0%) and valuation multiples (TRVI N/M vs DMAC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TRVI vs DMAC Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) is the stronger overall head-to-head candidate over Trevi Therapeutics, Inc. (TRVI) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). TRVI carries a Unified Composite Score of 42.9/100 (HOLD) at $13.34 (N/M Forward P/E, 0.0% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Technically, TRVI sits in a Neutral phase (RSI 46.0, CONSOLIDATION options structure) and DMAC sits in a Neutral phase (RSI 44.7, SURGE options structure).
TRVI leads the Growth & Scale pillar: TRVI posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TRVI generates N/A in USD-normalized revenue versus N/A for DMAC. In operating R&D and SG&A reinvestment, TRVI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.
TRVI and DMAC trade at balanced relative valuation multiples. TRVI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TRVI (-24.7% ROE) versus DMAC (-114.6% ROE) capital efficiency.
In options market volatility and institutional positioning, TRVI carries 62.3% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.49β · 76% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.